s2-013 cell line  (Eppley Laboratory Inc)

Journal: Oncotarget

Article Title: Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors

doi: 10.18632/oncotarget.26880

Figure Lengend Snippet: ( A ) Whole-body in vivo imaging of the S2-013 tumor-bearing mice after intravenous injection of Alexa 647-labeled scrambled control siRNA-COL and Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles via the tail vein. Fluorescence intensity of the Alexa 647-labeled nanoparticles, which accumulated in S2-013-derived PDAC tumors, was measured 24 h after intravenous injection into the mice. ( B ) The S2-013 tumor-bearing mice were fixed by perfusion 24 h after intravenous injection of Alexa 647-labeled scrambled control siRNA-COL and Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles via the tail vein. Representative confocal immunofluorescence microscopic images of frozen sections of S2-013-derived PDAC tumor tissues from mice showing scrambled control siRNA-COL (red) and the siRNA-FA-PEG-COL nanoparticles (red). Blue, DAPI staining. Scale bars, 10 μm.

Article Snippet: The human PDAC cell line S2-013, which is a subline of SUIT-2, the human PDAC cell line PANC-1, and HPNE immortalized normal pancreatic epithelial cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Carlsbad, CA, USA) containing 10% fetal calf serum as published previously [ ].

Techniques: In Vivo Imaging, Injection, Labeling, Control, Fluorescence, Derivative Assay, Immunofluorescence, Staining

Journal: Oncotarget

Article Title: Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors

doi: 10.18632/oncotarget.26880

Figure Lengend Snippet: ( A ) Ex vivo images of the PDAC tumors excised from the S2-013 tumor-bearing mice after intravenous injection of Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles (Scr), Alexa 647-labeled CCDC88A siRNA-FA-PEG-COL nanoparticles (siCCDC88A), and Alexa 647-labeled WASF2 siRNA-FA-PEG-COL nanoparticles (siWASF2) via the tail vein. The peritoneal dissemination nodule and mouse heart were excised from the S2-013 tumor-bearing mice after intravenous injection of Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles. Fluorescence intensity of the Alexa 647-labeled nanoparticles was measured 24 h after intravenous injection to the mouse model. ( B ) The S2-013 tumor-bearing mice were fixed by perfusion 24 h after intravenous injection of Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles (Scr) or Alexa 647-labeled target siRNA-FA-PEG-COL nanoparticles against CCDC88A (siCCDC88A) and WASF2 (siWASF2) via the tail vein. Frozen sections of S2-013-derived PDAC tumor tissues were immunocytochemically stained with antibodies corresponding to the target siRNAs (green). Nanoparticles were indicated by red. Representative confocal immunofluorescence microscopic images are shown. Arrows, tumor cells showing suppression of the target proteins by the siRNA-FA-PEG-COL nanoparticles. Arrows, the target siRNA-FA-PEG-COL nanoparticle transfected tumor cells that suppress CCDC88A or WASF2. Arrowheads, the scrambled control siRNA-FA-PEG-COL nanoparticle transfected tumor cells that express CCDC88A and WASF2. Blue, DAPI staining. Scale bars, 10 μm.

Article Snippet: The human PDAC cell line S2-013, which is a subline of SUIT-2, the human PDAC cell line PANC-1, and HPNE immortalized normal pancreatic epithelial cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Carlsbad, CA, USA) containing 10% fetal calf serum as published previously [ ].

Techniques: Ex Vivo, Injection, Labeling, Control, Fluorescence, Derivative Assay, Staining, Immunofluorescence, Transfection

Journal: Oncotarget

Article Title: Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors

doi: 10.18632/oncotarget.26880

Figure Lengend Snippet: ( A ) Development of carcinomatosis in S2-013 tumor-bearing mice treated with scrambled control siRNA-FA-PEG-COL nanoparticles. Arrow, primary tumor; arrowheads, dissemination nodules in the abdominal cavity. ( B – D ) Hematoxylin and eosin staining of representative sections of S2-013-derived PDAC tumor tissues in mice treated with scrambled control siRNA-FA-PEG-COL nanoparticles showing areas of regional invasion of the retroperitoneum (B), and distant metastases to the liver (C) and lung (D). Original magnification: × 200

Article Snippet: The human PDAC cell line S2-013, which is a subline of SUIT-2, the human PDAC cell line PANC-1, and HPNE immortalized normal pancreatic epithelial cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Carlsbad, CA, USA) containing 10% fetal calf serum as published previously [ ].

Techniques: Control, Staining, Derivative Assay

Journal: Oncotarget

Article Title: Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors

doi: 10.18632/oncotarget.26880

Figure Lengend Snippet: ( A ) Representative S2-013-derived PDAC tumor tissues in S2-013 tumor-bearing mice treated with scrambled control siRNA-FA-PEG-COL nanoparticles (Scr) and target siRNA-FA-PEG-COL nanoparticles against mRNAs for LAMTOR2 (siLAMTOR2), mTOR (simTOR), and NUP85 (siNUP85). Arrow, primary tumor; arrowheads, dissemination nodules in the abdominal cavity. ( B ) Hematoxylin and eosin staining of representative sections of S2-013-derived PDAC tumor tissues in mice treated with scrambled control siRNA-FA-PEG-COL nanoparticles or target siRNA-FA-PEG-COL nanoparticles against mRNAs for LAMTOR2 , mTOR , and NUP85 .

Article Snippet: The human PDAC cell line S2-013, which is a subline of SUIT-2, the human PDAC cell line PANC-1, and HPNE immortalized normal pancreatic epithelial cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Carlsbad, CA, USA) containing 10% fetal calf serum as published previously [ ].

Techniques: Derivative Assay, Control, Staining